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Abstract
HIV/AIDS trends in the United States depict a concentrated epidemic with hot spots that vary by
location, poverty, race/ethnicity, and transmission mode. HIV/AIDS is a leading cause of death
among US women of color; two thirds of new infections among women occur in black women,
despite the fact that black women account for just 14% of the US female population. The gravity
of the HIV epidemic among US women is often not appreciated by those at risk as well as by the
broader scientific community. We summarize the current epidemiology of HIV/AIDS among US
women and discuss clinical, research, and public health intervention components that must be
brought together in a cohesive plan to reduce new HIV infections in US women. Only by
accelerating research and programmatic efforts will the hidden epidemic of HIV among US
women emerge into the light and come under control.
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HIV incidence in the United States has remained an estimated 56,000 cases annually since
1991.1 The lack of substantive progress in reducing new HIV infections for almost 20 years
is noteworthy despite remarkable advances,2 including the advent of rapid HIV testing, opt-
out testing, and a variety of potent once-daily antiretroviral therapies as well as the
availability of evidence-based behavioral interventions.3
Unlike the generalized epidemic in regions of sub-Saharan Africa, the US HIV epidemic is
concentrated among certain subpopulations, particularly men who have sex with men
(MSM) and persons of color.4 Although the high HIV prevalence among MSM in the
United States is well recognized, the impact of HIV on women is less widely appreciated.
Moreover, women at risk for HIV acquisition frequently do not appreciate this risk. The
HIV epidemic among US women is, in many ways, hidden from effective dialogue, both
among the populations at risk and within the broader scientific community. We summarize
current epidemiology of HIV/AIDS among US women and discuss critical components that
must be brought together in a cohesive plan to reduce new HIV infections in US women.
DISCUSSION
Epidemiology of HIV in US Women
Prevalence and incidence trends depict a concentrated epidemic with hot spots that vary by
location, poverty rate, race/ethnicity, and transmission mode. By 2006, an estimated 1.1
million adults and adolescents were HIV infected; approximately 21% of HIV-infected
individuals were unaware of their HIV infection.5,6 Although HIV incidence estimates
peaked at 150,000 cases per year during the mid 1980s, followed by a plateau at about
56,000 cases per year since 1991,1 the annual rate of new HIV cases has been increasing in
certain subgroups, particularly MSM and black and Latina women. Eighty per cent of HIV
cases in women occur in black and Hispanic women, who together constitute just 25% of the
US female population.7 Using back-calculation modeling, Rosenberg and Biggar reported
that although HIV incidence was declining in white men aged 20 to 25 years, it was
increasing in women in the same age group.8
The HIV epidemic among US women is concentrated in the Northeast and South, with a
significantly higher proportion of HIV infections occurring in areas with high poverty rates.9
Heterosexual activity has been the major mode of HIV acquisition for US women since
1995, when it surpassed injection drug use (IDU).10 Of women newly identified as HIV
infected, 83% are estimated to have acquired HIV heterosexually, with most of the
remaining acquiring HIV through IDU.7
Trends in AIDS rates among US women are of particular concern. Although women
accounted for only 15% of AIDS cases from 1981 to 1995, they accounted for 27% of AIDS
cases from 2001 to 2004.11 The CDC reported a 15% increase in AIDS cases among women
from 1999 to 2003, compared to a 1% increase in men.11 In addition, estimated AIDS
diagnoses are 23 times greater in black women than in white women.12
Mortality trends among women with HIV are striking. Although the death rate due to HIV
has decreased, HIV remains the third most common cause of death among black women
aged 35 to 44 and the fourth most common cause of death among younger black women
aged 25 to 34.12 The age-adjusted annual death rate due to HIV among black women during
2001–2005 was higher than that observed in every racial/ethnic group except non-Hispanic
black males.13 Similarly, when compared to white women, black women with HIV have a
13-fold mortality risk ratio.14
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Why Are Women at Risk for HIV?
Many factors contribute to HIV acquisition among women. Gender inequalities, both social
and economic, hamper some women’s abilities to negotiate condom use and other safer sex
behaviors.15,16 Interpersonal violence is a risk factor for HIV among women, regardless of
race or ethnicity.17 Factors associated with transmission of HIV and other sexually
transmitted infections (STIs) include poverty, lack of access to medical care, poor
knowledge about HIV/AIDS, lower social status,18,19 financial dependence on male
partners, assortative mixing within the high-HIV prevalence African American
community,20 feelings of invincibility, low self-esteem, and alcohol and drug use.21
However, individual risk behaviors do not explain the dramatic racial disparities in STI and
HIV rates.22,23 In one study, black men and women with “low-risk” behaviors had 25-fold
higher incidence of HIV and STIs compared with their white counterparts,23 a disparity that
remains unexplained. Black women may underestimate the HIV risk status of their male
partners; 6% of HIV-infected black women versus 14% of HIV-infected white women
reported having a bisexual male partner, despite the fact that more than twice as many black
HIV-infected men as white HIV-infected men (34% vs 13%) reported sex with both men
and women.24 More black men and women than white25,26 are unaware of their HIV
infection. These data may reflect a number of factors, including differences in HIV testing
uptake and HIV prevalence as well as treatment and structural features of the social
environment. Sexual networks shaped not only by individual preferences and behaviors but
also by macroeconomic, political, societal, and other structural features of the environment
play a critical role in HIV acquisition among women.20,27,28 Concurrent sexual partnerships
can amplify HIV transmission, particularly when one partner has early HIV infection, a
period with high transmissibility.27,29 The higher prevalence of concurrent partnerships
observed in US black and Hispanic men may contribute to racial disparities in HIV rates
among US women.30 Sexual mixing patterns connecting women at low risk for HIV with
men at higher risk may increase HIV acquisition in women; such mixing patterns have been
observed among black men and women in the South.20
Recent studies demonstrate strong associations between prior incarceration9 or incarceration
of a partner31 with HIV infection in US women. Though correctional inmates may view
themselves at low or no risk for HIV acquisition,32 HIV prevalence among prisoners is more
than 2.5 times higher than the general US population with a relatively high proportion of
HIV-infected persons passing through the correctional system.33–35 The racial disparity of
incarceration is striking: 1 in 9 black men between the ages of 20 and 34 is incarcerated,
compared with 1 in 30 US men in the same age group.36 Incarceration influences sexual
networks by disrupting stable sexual partnerships and has been associated with concurrent
partnerships and dissortative mixing that promote HIV transmission.20,31,37 To date,
incarceration has not been consistently used as an HIV prevention opportunity; condoms and
clean injection equipment are unavailable to inmates in some correctional systems.
Similarly, HIV testing policies vary widely among correctional systems.
HIV Prevention for US Women: Current Status
Early domestic HIV prevention successes included implementation of mandatory blood
product screening and effective programs for prevention of mother-to-child transmission.2
Harm reduction programs throughout the United States have contributed to sharp declines in
new HIV diagnoses among IDUs.38,39
Unfortunately, although consistent male condom use is known to be efficacious in reducing
HIV transmission40 and female condoms have been assumed to be similar to male condoms
in preventing HIV,41 condom implementation has not been effectively realized to decrease
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numbers of new HIV infections. Over the past decade, multiple microbicide trials have been
disappointing.42–46 However, a number of ongoing trials are assessing new vaginal
microbicides as well as antiretroviral drugs for pre-exposure prophylaxis,47,48 and results
from the CAPRISA 004 microbicide study (a double-blind randomized placebo-control
study among 989 women) recently demonstrated tenofovir 1% vaginal gel to have 40%
efficacy in preventing HIV acquisition.49 To date, multiple vaccine trials have failed to
prevent HIV transmission,50,51 with the possible exception of a recombinant canarypox
vector vaccine (ALVAC-HV) plus two booster injections of recombinant gp 120, which
demonstrated vaccine efficacy of 31.2% (95% CI 1.1–52.1; P=0.04) in modified intent-to-
treat analysis.52 Although statistically significant and perhaps useful to inform development
of future vaccines, this 6-injection vaccine series did not demonstrate statistically significant
efficacy in the per protocol analysis and had no effect on the level of HIV-1 viremia.
Antiretroviral treatment as a strategy to decrease HIV transmission has been the subject of
recent interest.53–56 However, individuals with known HIV infection in the United States
confront an array of barriers to health care access, medication adherence, and achievement
of optimal virologic outcomes needed for this approach to effectively prevent HIV
transmission.57
Multiple behavioral interventions to prevent HIV acquisition by women have been
developed. However, a recent review of this area identified only 7 behavioral interventions
demonstrating subsequent reductions in unprotected sexual intercourse3 and STIs,58,59 and
none of the studies used HIV incidence as an end point. An additional limitation of most of
these studies was a requirement that participating women attend multiple sessions, limiting
the feasibility of broad implementation of these interventions in at-risk communities.
Furthermore, few of the interventions attempted to directly influence social networks or
sexual behaviors of women’s partners—a critical component to HIV prevention in US
women.60–62 Of 11 interventions listed as effective for women of color by the CDC,63 none
have assessed effect on HIV acquisition.
THE WAY FORWARD
Four areas must be urgently addressed to effectively decrease new HIV infections in US
women. First, an absence of rigorous HIV incidence data among at-risk women impedes
design of prevention trials with HIV incidence as primary end point; sample size
calculations are not feasible without reliable estimates of incidence in the target population.
Second, behavioral strategies addressing male partners of women are needed. To date, only
limited research has attempted to alter the sexual attitudes and behaviors of heterosexual and
bisexual men.58,61,62 Research evaluating strategies that favorably influence gender norms
and behaviors of men are critically needed. Although data suggest that sexual networks may
be effectively used to identify cases of undiagnosed HIV,64 few sexual or social network
interventions have been evaluated in women.65
Third, expanded HIV testing and linkage to care, and effective antiretroviral treatment of
individuals with HIV are critical to successful HIV prevention. Novel programs must be
developed to facilitate effective virologic suppression among persons living in social chaos
(ie, high poverty rates, high community violence, homelessness, and fragile social supports).
Finally, it is heartening that a national HIV/AIDS Strategy for the United States has recently
been created.66 Moving forward, we must assure that HIV prevention plans continue to
recommend implementation of proven strategies as well as promptly incorporating future
HIV prevention trial results.
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The ongoing HIV epidemic among US women, particularly black and Hispanic women,
must receive the attention it is due. Research is needed to identify effective interventions
that decrease US women’s risk of HIV infection and are feasible to scale up in these
populations. In addition, there is an urgent need to establish programs that enable US
women to protect themselves. New, innovative prevention programming must build upon
knowledge gained from past HIV prevention trials. Equally critical is the effective
implementation of a multidimensional HIV prevention plan incorporating community,
correctional institutions, and treatment programs (including support services such as
substance abuse programs). Only by accelerating both research and programmatic efforts
will the hidden epidemic of HIV among US women emerge into the light and be effectively
addressed.
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